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antiparkinson agent pramipexole dihydrochloride monohydrate in 
pharmaceutical products
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The antiparkinson agent pramipexole dihydrochloride monohydrate was quantified in pharmaceutical 
products by high performance liquid chromatography (HPLC) and derivative spectrophotometry. The first 
method was based on HPLC using tamsulosin HCl as an internal standard. In this method, chromatographic 
separation was achieved using a LiChrospher 60 RP column at 25°C, with a flow rate of 1.0 mL/min at 
263 nm. The eluent comprised 0.01 mol/L ammonium acetate (pH 4.4) and acetonitrile (35:65 by volume). 
The linearity range was found to be 10.0-30.0 µg/mL with a mean recovery of 100.5 ± 1.10. The limit 
of detection (8 ng/mL) and limit of quantification (50 ng/mL) were calculated. In the second method, 
the first derivative spectrophotometric technique for the determination of pramipexole dihydrochloride 
monohydrate was performed by measuring the amplitude at 249 and 280 nm. In the first derivative 
technique, the absorbance and concentration plot was rectilinear over the 5.0-35.0 µg/mL range with a 
lower detection limit of 1.5 ng/mL and quantification limit of 4.5 ng/mL. The typical excipients included in 
the pharmaceutical product do not interfere with the selectivity of either method. The developed methods 
were validated for robustness, selectivity, specificity, linearity, precision, and accuracy as per the ICH and 
FDA guidelines (ICH Q2B, 1996; FDA,2000). In conclusion, the developed methods were successful 
in determining the quantity of the antiparkinson agent pramipexole dihydrochloride monohydrate in 
pharmaceutical products. The RSD values for the pharmaceutical product used in this study were found 
to be 0.97% for the HPLC method and 0.00% for the first derivative spectrophotometric method.
Uniterms: Antiparkinson agent/determinação. Pramipexole dihydrochloride monohydrate. 
Pharmaceutical product/quality control. High performance liquid chromatography/quantitative analysis. 
Derivative spectrophotometry/quantitative analysis.
O fármaco antiparkinsoniano, dicloridrato de pramipexol monoidratado, foi quantificado no produto 
farmacêutico por cromatografia líquida de alta eficiência (CLAE) e espectrofotometria derivada. No 
primeiro método baseado na CLAE, o cloridrato de tansulosina foi usado como padrão interno. Nesse 
método, a separação cromatográfica foi realizada usando uma coluna Lichrosper 60 RP a 25 °C e 
acetato de amônio 0,01 mol/L (pH:4.4): acetonitrila (35:65 em volume) como eluente com fluxo de 1,0 
mL /min a 263 nm. A faixa de linearidade foi de 10.0-30.0 µg/mL com média da recuperação 100.5 
± 1.10. O limite de detecção (8 ng/mL) e o limite de quantificação (50 ng/mL) foram calculados. Por 
outro lado, a primeira técnica de espectrofotometria derivada para a determinação de dicloridrato de 
pramipexol monoidratado foi realizada através da medida da amplitude a 249 e 280 nm. Na técnia da 
primeira derivada, a absorvância e a plotagem da concentração foi retilínea na faixa de 5.0-35.0 µg/mL 
com limite inferior de detecção de 1.5 ng/mL e limite de quantificação de 4.5 ng/mL. Os excipientes 
típicos incluídos no produto farmacêutico não interferem com a seletividade dos métodos. Os métodos 
desenvolvidos foram validados quanto à robustez, seletividade, especificidade, linearidade, precisão e 
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exatidão de acordo com as diretrizes do ICH e FDA (ICH Q2B,1996; FDA,2000). Concluindo, os métodos 
propostos foram aplicados com sucesso para a determinação quantitativa do agente antiparkinsoniano 
dicloridrato de pramipexol monoidrato em produtos farmacêuticos. Os valores de RSD para o produto 
farmacêutico utilizado neste estudo foi 0.97% para a CLAE e 0.00% para o método de espectrofotometria 
de primeira derivada.
Unitermos: Agente antiparkinsoniano/determinação. Dicloridrato de pramipexol monoidrato. Produto 
farmacêutico/controle de qualidade. Cromatografia líquida de alta eficiência/análise quantitativa. 
Espectrofotometria derivada/análise quantitativa.
INTRODUCTION
The chemical name of pramipexole dihydrochloride 
monohydrate is (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-
benzothiazole-2,6-diamine dihydrochloride monohydrate 
(Figure 1). The structural formula is given below (O’Neil 
et al., 2006).
Pramipexole is a non-ergot dopamine agonist. 
Pramipexole alleviates parkinsonian motor deficits by 
stimulation of dopamine receptors in the striatum. It may 
be used as monotherapy or in combination with levodopa. 
Pramipexole is indicated for the treatment of the signs 
and symptoms of idiopathic Parkinson’s disease and 
the symptomatic treatment of idiopathic Restless Legs 
Syndrome (Physicians’ Desk Reference, 2013).
Many analytical methods for the measurement of 
pramipexole in pharmaceutical dosage forms or biological 
fluids have been reported. Those methods are based on 
spectrophotometry (Armağan, 2011; Babu, Raju, 2007; 
El-Bayoumi, 2009; Gurupadayya, Vishwajith, Srujana, 
2009; Rani, Reddy, 2006; Rani, Reddy, 2007; Thangabalan 
et al., 2011a,b), high-performance liquid chromatography 
(HPLC) (El-Sherif, Abdel-Fattah, El-Houssini, 2008; Hua 
et al., 2011; Jancic et al., 2007a,b; Kamienska-Duda, 
Kosmacinska, 2008; Malenovic et al., 2010; Manish et al., 
2010; Ramakrishna et al., 2007; Rao et al., 2009; Shuhui, 
2010; Srinubabu et al., 2006; Syeda et al., 2010; Vijaya et 
al., 2009), gas chromatography (Panchal, Patel, Menon, 
2011), and capillary electrophoresis (Musenga et al., 2008; 
Chang-Hai et al., 2009).
Easy, rapid, and economical analytical methods are 
desirable in order to achieve routine quality control testing 
of drugs. The objective of the present study was to develop 
and validate a new simple, efficient, selective, precise, and 
reproducible method for routine quality control analyses 
of commercial pharmaceutical dosage forms containing 
pramipexole. Both HPLC and the spectrophotometric 
methods have been widely applied because they sensitive, 
reproducible, and precise.
EXPERIMENTAL
Chemicals
The pramipexole dihydrochloride monohydrate 
standard sample was provided by Orchid Chemicals and 
Pharmaceuticals Ltd (Maharashtra, India) and the internal 
standard (IS), tamsulosin HCl, was obtained from Titan 
Laboratories Pvt Ltd (Maharashtra, India). Acetonitrile, 
glacial acetic acid 100%, ammonium acetate EMSURE® 
ACS Reagent, and HPLC-grade water were supplied from 
J.T. Baker (Deventer, Netherlands). The HCl 37% ACS 
reagent was obtained from Merck (Darmstadt, Germany). 
All other reagents were of analytical grade, and were used 
as received.
Instrumentation and analytical conditions
The HPLC system consisted of a membrane 
degasser, a quartet gradient pump, a 100 µL cyclic 
injection valve, an autosampler with 100 vials, and a 
UV/Vis detector (1200 Series, Agilent Technologies, 
USA). A reversed phase Merck brand LiChrospher 60 
RP-Select B (125 x 4.0 mm, 5µm) column was used. The 
mobile phase was composed of 0.01 mol/L ammonium 
acetate (pH 4.4) and acetonitrile (35:65 by volume). The 
solution was filtered through a 0.20 µm membrane filter 
and degassed by sonication before use. The flow rate 
was 1.0 mL/min, the column temperature was 25 °C, the 
detector wavelength was set at 263 nm, and the injection 
volume was 20.0 µL. The peak areas were integrated 
automatically with Windows NT based LC ChemStation 
Software.
FIGURE 1 – Structure of pramipexole dihydrochloride 
monohydrate.
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The spectrophotometric analysis was performed 
using a Shimadzu UV-1601 UV/Visible double beam 
spectrophotometer. The cells used for absorbance 
measurements were 10 mm path length quartz cells. 
Derivative conditions were as follows: scan speed, 
60.0 nm/min; spectral slit width, 2.0 nm; ∆λ, 6.0 nm.
Development of the HPLC and 
spectrophotometric methods
During the development of the HPLC method, 
the appropriate diluent and internal standard were first 
chosen. Pramipexole dihydrochloride monohydrate was 
best dissolved in water, and it was established visually that 
water was also the best diluent for the internal standard 
tamsulosin HCl.
After evaluating different columns, the most 
appropriate one was chosen. During this process, it was 
observed that the RP8, C8, and C18 columns did not 
show resolution of the pramipexole dihydrochloride 
monohydrate and internal standard peaks. The best 
resolution was achieved using the RP-Select B 
column.
Different mobile phases were tried and the mobile 
phase that showed the best peak performance was chosen. 
When a 25:75 volume ratio of 0.01 mol/L ammonium 
acetate (pH 4.4) and acetonitrile was used as the mobile 
phase, the resolution achieved was low and the internal 
standard and pramipexole peaks were close to each other. 
When a 50:50 volume ratio of 0.01 mol/L ammonium 
acetate (pH 4.4) and acetonitrile was used as the mobile 
phase, the plate number was low. The mobile phase that 
showed the best tailing factor, resolution, and plate number 
was a 35:65 volume ratio of 0.01 mol/L ammonium acetate 
(pH 4.4) and acetonitrile.
The wavelength that showed maximum absorbance 
for pramipexole dihydrochloride monohydrate in the 
UV spectrophotometry, 263 nm, was tested in the HPLC 
method. It was concluded that the maximum absorbance 
wavelength in the HPLC method for pramipexole 
dihydrochloride monohydrate and the internal standard 
(tamsulosin HCl) was also 263 nm. To show the robustness 
of this method, first the mobile phase flow rate was 
changed (1 ± 0.2 mL/min), and later the pH of the mobile 
phase was changed (pH 4.4 ± 0.05).
During the development of the spectrophotometric 
method, the appropriate diluent was chosen. It was 
proven that the maximum absorbance wavelength of 
the chosen diluent was 263 nm. In the first derivative 
spectrophotometric technique, recovery was found to 
be high and the RSD value was found to be low at the 
maximum absorbance levels observed (249 nm and 
280 nm).
Preparation of standard and sample solutions
Preparation of internal standard, standard stock, and 
standard solutions for the HPLC method
Using water as a solvent, the internal standard 
solution of tamsulosin HCl was prepared at a concentration 
of 100.0 µg/mL. The standard stock solution (250.0 µg/mL) 
was prepared from the internal standard solution. In order to 
construct a calibration curve, pramipexole dihydrochloride 
monohydrate standards were prepared from the standard 
stock solution in the concentration range 10.0-30.0 µg/mL, 
using the internal standard solution as a solvent.
Preparation of solution for spectrophotometric 
method
The standard stock solution of 1000 µg/mL was 
prepared by dissolving 50 mg pramipexole dihydrochloride 
monohydrate in 50 mL of 0.1 mol/L HCl. From the stock 
solution, seven different concentrations were prepared 
in 100 mL volumetric flasks, at a concentration range of 
5.0-35.0 µg/mL, using 0.1 mol/L HCl as a diluent. The 
calibration curves were created from these seven solutions. 
The absorbance of the standard solutions were recorded 
against a blank sample of 0.1 mol/L HCl. After recording 
the zero order spectra, the first derivatives of the above 
absorption spectra were determined and recorded.
Sample preparation
Tw e n t y  t a b l e t s  c o n t a i n i n g  p r a m i p e x o l e 
dihydrochloride monohydrate were precisely weighed 
and ground into a fine powder. For the HPLC method, 
a quantity of the powder equivalent to one tablet weight 
was transferred to a 50 mL volumetric flask containing 
the internal standard solution and stirred for 20 min with 
a magnetic stirrer. In the spectrophotometric method, 
a quantity of the powder equivalent to one tablet was 
transferred into a 50 mL volumetric flask containing 
0.1 mol/L HCl. Prepared solutions were filtered through 
a 0.20 µm membrane filter and the filtered liquid was 
subsequently used for the tests. Quantification was 
achieved by means of the calibration curve method, which 
was established using the calibration results.
Validation of the analytical methods
The described HPLC and spectrophotometric 
methods have been validated according to ICH (Q2B, 
1996) and FDA (2000) guidelines.
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Robustness
The robustness of the method was determined by 
varying the pH from 4.35 to 4.45 and the flow rate from 
0.8 to 1.2 mL/min. Moreover, the stability of the prepared 
standard solution and sample solutions, including the 
placebo and pramipexole dihydrochloride monohydrate 
at the concentration of 20.0 µg/mL was evaluated via 
analysis after 3, 6, 12, 24 and 48 hours.
Selectivity and specificity
In order to determine the specificity of both methods, 
1.0 mg pramipexole dihydrochloride monohydrate was 
added to the placebo, which contained 42.0 mg of each 
excipient found in the tablet form. These excipients 
are mannitol, colloidal silicone dioxide, corn starch, 
Polyvidone K25, and magnesium stearate. All precisely 
weighed components were transferred into volumetric 
flasks and dissolved by shaking with internal standard 
and 0.1 mol/L HCl and the solutions were filled up to the 
volume mark with diluent. After dilution, solutions were 
filtered through a 0.20 µm membrane filter and analyzed 
in both methods under specified conditions.
Linearity of calibration and limits of detection and 
quantification
To test the linearity, five different concentration 
levels ranging from 10.0–30.0 µg/mL for the HPLC 
method and seven different concentrations of standard 
solutions from 5.0–35.0 µg/mL for the spectrophotometric 
method were used in order to construct calibration 
curves. For both methods, solutions were prepared in 
triplicate. In the HPLC method, a calibration curve was 
constructed using the least squares method by plotting 
the peak area ratios versus concentration of pramipexole 
dihydrochloride monohydrate and the linear regression 
equation was used to determine linearity. Under defined 
chromatographic conditions, the detector response for 
the peak area ratio of pramipexole dihydrochloride 
monohydrate to tamsulosin HCl (IS) in the HPLC studies 
was observed and it was shown that the calculated ratio was 
proportional to pramipexole dihydrochloride monohydrate 
concentration. Linear regression analysis was performed 
in order to determine the correlation coefficients. In the 
spectrophotometric method, a calibration curve was 
constructed using the least squares method by plotting 
the derivative absorbances versus the concentration of 
pramipexole dihydrochloride monohydrate for the first 
derivative of the spectra. The limit of detection (LOD) 
is defined as the lowest amount of analyte in a sample 
that can be detected but not necessarily quantified to 
an exact value. The limit of quantification is the lowest 
amount of substance that can be quantified precisely and 
accurately. For both methods, the LOD (detection limit) 
and LOQ (quantification limit) were calculated based on 
the response and slope of the regression equation.
Precision
For the precision of the HPLC method, pramipexole 
dihydrochloride monohydrate standard solutions were 
evaluated six times at specified intervals (time = 0, 30th 
minute, 1st, 2nd, 5th and 10th hour) in order to achieve 
repeatability in the same day (intra-day precision). For 
inter-day precision, the solutions were tested on 3 different 
days, 3 times each day, in order to achieve inter-day 
precision.
The precision of the spectrophotometric method was 
determined by pramipexole dihydrochloride monohydrate 
standard solutions which were tested at five specified 
intervals (time = 0, 1st, 2nd, 3rd and 4th hour) in order to 
achieve repeatability in the same day (intra-day precision). 
The solutions were also tested on 4 different days, 3 
times each day, for inter-day precision in order to achieve 
reproducibility.
Accuracy
For both methods, accuracy was investigated by the 
determination of the drug substance (active substance) 
in the presence of various excipients like mannitol, 
colloidal silicone dioxide, corn starch, Polyvidone K25 
and magnesium stearate. In the HPLC method, samples are 
prepared by mixing the same amount of placebo mixture 
(~840 mg) with 5 different amounts (between 50-150%) of 
the active substance. The sample solutions were injected 
under specified conditions and peak area ratios were 
recorded. In the spectrophotometric method, accuracy was 
analyzed by using the same amount of placebo mixture 
(~420 mg) with 3 different amounts (between 25-175%) 
of active substance.
The procedures above were repeated three times.
RESULTS AND DISCUSSION
In this paper, two newly developed techniques (using 
HPLC and spectrophotometric methods) were proposed 
for pramipexole dihydrochloride monohydrate assay in 
pharmaceutical dosage forms.
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TABLE I - System suitability parameters for the quantification of pramipexole in tablets by HPLC
Variations
Pramipexole/IS 
Retention Time
Pramipexole/IS 
Area/Ratio
Retention Factor Tailing Factor Plate Number Resolution
Mobile Phase 
(25:75, v/v)
2.63/ 3.07 0.87 4.26 1.46 2497 2.03
Mobile Phase 
(35:65, v/v) 
(Original)
2.07/ 3.05 0.90 3.13 1.40 2071 4.87
Mobile Phase 
(50:50, v/v)
1.77/3.86 0.83 2.54 1.36 1145 7.87
FIGURE 2A - Chromatogram of pramipexole dihydrochloride monohydrate (20.0 µg/mL) with tamsulosin HCl (100.0 µg/mL) as 
the internal standard.
FIGURE 2B - Peak performance evaluation of pramipexole dihydrochloride monohydrate.
Optimization of the chromatographic conditions
To optimize the proposed HPLC method, all of 
the experimental conditions were investigated. For this 
purpose the following mobile phases were tried: 1) 
ammonium acetate: acetonitrile (25:75, by volume); 2) 
ammonium acetate: acetonitrile (35:65, by volume); and 
3) ammonium acetate: acetonitrile (50:50, by volume), 
at a flow rate of 1.0 mL/min. The best resolution was 
achieved when using a mobile phase consisting of 
ammonium acetate: acetonitrile (35:65, by volume). The 
results obtained regarding the variation in mobile phase 
ratios are shown below in Table I. The stationary phases 
RP-Select B, RP-8, C8, and C18 were used. The optimum 
chromatographic performance was achieved when using 
Merck LiChrospher 60 RP-Select B 125 x 4.0 mm, 5 µm 
(Figures 2a, 2b). The other stationary phases were found 
to be ineffective for the determination of system suitability 
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parameters, as symmetrical and uniform peaks could not 
be obtained.
The robustness of the proposed method was 
evaluated by varying the pH from 4.35 to 4.45, which 
resulted in no effect on the chromatographic conditions. 
The mobile phase flow rate was changed between 0.8 
and 1.2 mL/min. When the flow rate was lowered to 0.8 
mL, the retention time increased to 2.58 minutes, while 
increasing the flow rate to 1.2 mL decreased the retention 
time to 1.72 minutes. The results are presented in Table II.
According to studies, tamsulosin HCl is used as 
an internal standard because it gives a good response 
in experimental conditions and does not interfere with 
other peaks. The elution was monitored in the whole 
UV spectrum to determine the optimum selectivity and 
detectivity. The results indicated that the wavelength of 
263 nm should be selected for the detection of pramipexole 
dihydrochloride monohydrate and tamsulosin HCl 
(IS) since it demonstrated the greatest response in the 
experiment.
The stability of standard stock solutions and sample 
standard solutions were also assessed. The results show 
that, over a 48 h period at room temperature (30 °C), 
the change in quantity of pramipexole dihydrochloride 
monohydrate in the standard solution was 0.36 % and 
the change in quantity of pramipexole dihydrochloride 
monohydrate in the sample solution that contains placebo 
was 0.17%. These results are shown in Table III below. 
TABLE II - Results of robustness test of the HPLC method (variation of the pH and flow rate of the mobile phase)
Variations
Pramipexole 
Retention Time
Pramipexole/IS 
Area/Ratio
Retention 
Factor
Tailing 
Factor
Plate 
Number
Resolution
Mobile Phase 
0.01 mol/L AA pH; 4.35
1.96 0.94 2.91 1.30 2041 4.92
Mobile Phase 
0.01 mol/L AA pH; 4.40 
(Original)
1.96 0.93 2.92 1.31 2047 4.95
Mobile Phase 
0.01 mol/L AA pH; 4.45
1.96 0.92 2.92 1.31 2052 4.87
Mobile Phase 
Flow Rate: 0.8 L/min
2.58 0.94 4.15 1.39 2142 5.43
Mobile Phase 
Flow Rate: 1.0 mL/ min 
(Original)
2.06 0.94 3.12 1.36 2043 5.25
Mobile Phase  
Flow Rate: 1.2 L/min
1.72 0.94 2.43 1.33 1674 4.99
TABLE III - Results of robustness test of the HPLC method (solution stability)
STANDARD 
Pramipexole 
Area (mAU)
% Change
STANDARD 
IS Area 
(mAU)
% Change
SAMPLE  
Pramipexole 
Area (mAU)
% Change
SAMPLE 
IS Area 
(mAU)
% Change
Time = 0 499.3 - 529.6 - 515.3 - 544.6 -
3rd hour 498.2 0.22 530.5 0.17 514.7 0.12 544.4 0.04
6th hour 497.8 0.30 532.7 0.58 516.9 0.31 546.2 0.29
12th hour 497.4 0.38 529.9 0.06 514.9 0.08 544.2 0.07
24th hour 498.6 0.14 530.5 0.17 514.6 0.14 544.6 0.00
48th hour 497.5 0.36 530.8 0.23 514.4 0.17 544.7 0.02
Mean 498.1 530.6 515.1 544.8
Standard 
Deviation 0.70 1.09 0.92 0.71
(RSD%) 0.14 0.20 0.18 0.13
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The specificity parameter of the HPLC method 
was analyzed to identify the interference of excipients 
by comparing the chromatograms of the drug substance 
and the most commonly used excipients mixture. The 
chromatograms obtained from the mixture containing the 
standard solution, and internal standard solutions from the 
placebo mixture and from the pharmaceutical product, are 
shown in Figures 3a, b, and c, respectively. As shown in 
Table IV, the results obtained exhibited no interference 
from excipients.
The precision of the HPLC method was determined 
by establishing the repeatability (intra-day) and 
reproducibility (inter-day) parameters of the pramipexole 
dihydrochloride monohydrate standard solutions. 
Moreover, injection repeatability was performed in 
order to confirm the performance of the HPLC method. 
The calculated RSD (relative standard deviation) values 
showed that the method exhibited good repeatability 
(<0.77) for intra-day and inter-day precision. The results 
confirmed the high precision of the HPLC method.
For the development of a sensitive derivative 
spectrophotometric method, 0.1 mol/L HCl was 
selected as a solvent system due to its sensitivity, lack 
of interference, ease of preparation, suitability for drug 
content estimation, and cost. The direct UV spectrum 
and the first derivative spectrum of pramipexole 
dihydrochloride monohydrate in 0.1 mol/L HCl solution 
are shown in Figures 4a and b, respectively. The 
derivative spectrophotometry technique was chosen 
for the determination of pramipexole dihydrochloride 
monohydrate s ince i t  could remove broadband 
contributions from excipients and overcome the 
interference caused by peak overlapping. Derivative 
spectra of different orders were studied for pramipexole 
FIGURE 3A – Chromatogram of mixture containing pramipexole standard solution and internal standard solution.
FIGURE 3B - Chromatogram of placebo mixture.
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FIGURE 3C - Chromatogram of pharmaceutical product.
TABLE IV - Results of specificity test of the HPLC method
Pramipexole 
Concentration 
(µg/mL)
IS (Tamsulosin HCl) 
Concentration 
(µg/mL)
HPLC Retention 
Time (Rt) Reading
HPLC Area Value 
(mAU) Reading
Mobile Phase - - - -
Internal Standard - 100 3.22 531.5
Placebo - 100 3.22 529.2
Pramipexole Working Standard 20 100 2.05 3.21
500.5 
530.4
Sample 20 100 2.05 3.21
513.4 
542.1
FIGURE 4A - Zero order UV scans pramipexole dihydrochloride monohydrate (20.0 µg/mL) in 0.1 mol/L HCl.
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TABLE V - Results of Specificity Test of the spectrophotometric method
Pramipexole 
Concentration (µg/mL)
1. DERIVATIVE
249 nm 280 nm
Placebo - 0.000 0.000
Pramipexole Working Standard 20 0.020 0.026
Sample 20 0.020 0.026
FIGURE 4B - First derivative spectra of pramipexole dihydrochloride monohydrate (20.0 µg/mL) in 0.1 mol/L HCl.
dihydrochloride monohydrate and experimental results 
showed that the first derivative spectra gave well-defined 
peaks around 249 and 280 nm, with suitable precision.
The first derivative method studies were evaluated 
and the precision parameter determined. The RSD (relative 
standard deviation) values were calculated and results 
indicated that the method demonstrated good repeatability 
(< 2.72) for intra-day and inter-day precision.
The specificity parameter of the first derivative 
spectrophotometric method was calculated to identify the 
interference from excipients by comparing the derivative 
spectra of the drug substance and the most commonly used 
excipient mixture. The resulting derivative spectra did not 
show any peak other than the standard solution, which 
demonstrated the specificity of the method. As shown in 
Table V, the results obtained showed no interference from 
excipients.
Assay performance of the present methods were 
evaluated by linearity, accuracy, precision, LOD, LOQ, 
stability and applicability in pharmaceutical dosage 
forms. The detector response for the peak area ratios of 
pramipexole dihydrochloride monohydrate to tamsulosin 
HCl (IS) in HPLC studies was observed under defined 
chromatographic conditions and it was recorded that 
the calculated ratio was proportional to pramipexole 
dihydrochloride monohydrate concentration. In addition, 
it was discovered that the signals recorded at around 
249 and 280 nm with the first derivative spectra were 
proportional to pramipexole dihydrochloride monohydrate 
concentration. To obtain calibration curves for both 
proposed methods, chromatograms and spectra were 
recorded at varying concentrations of pramipexole 
dihydrochloride monohydrate. For each concentration, 
measurements were performed at least three times. The 
characteristics of the calibration curves are summarized 
in Table VI. Under the experimental conditions, the limit 
of detection (LOD) and the limit of quantification (LOQ) 
were calculated using LOD=3s/m and LOQ=10s/m 
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(Varma, Kaushal, Garg, 2004) to evaluate the sensitivity 
of the proposed methods.
The accuracy of both methods was assessed 
by adding known concentrations of pramipexole 
dihydrochloride monohydrate to sample solutions and 
then comparing the results of measured and calculated 
concentrations. The accuracy of the HPLC and first 
derivative spectrophotometric techniques was determined 
and expressed in terms of percent recovery. The mean 
recovery and RSD values obtained were found to be 
100.5% and 1.10% for the HPLC technique and <107.6% 
and <4.36% for the first derivative spectrophotometric 
technique, respectively.
The  proposed  HPLC and  f i r s t  de r iva t ive 
spectrophotometric techniques were applied to the 
determination of pramipexole dihydrochloride monohydrate 
in the pharmaceutical product Pexola® Tablet 1.0 mg (Batch 
No: 206377, Exp. Date: 08.2015, Manufacturer: Boehringer 
Ingelheim Pharma GmbH & Co. KG., Germany).
The average weight, thickness, and diameter of 20 
Pexola® Tablets were measured and the results were as 
follows; average weight 209 mg, average thickness 2.65 
mm, average diameter 9.08 mm.
The results of the application of both the HPLC 
and the first derivative spectrophotometric methods for 
the quantitative analysis of pramipexole dihydrochloride 
monohydrate in Pexola® Tablet 1.0 mg are given in Table 
VII. The results show that both methods can be successfully 
applied for the assay of pramipexole dihydrochloride 
monohydrate in pharmaceutical products. The parameters 
regarding the chromatographic and spectrophotometric 
methods developed are given in Table VIII.
The precision of analytical methods was determined 
using the pharmaceutical product for which the methods 
were developed. Sample solutions have been prepared 
with 20 tablets of Pexola® Tablet 1 mg as described in 
the Experimental section. Prepared solutions were filtered 
through a 0.20 µm membrane filter and the filtered liquid 
was used for the analysis of both methods.
CONCLUSION
The proposed methods to determine pramipexole 
dihydrochloride monohydrate quantities in pharmaceutical 
products were proven to be fast, precise, and simple. They 
produce results at a low cost and experience minimal 
TABLE VI - Statistical analysis of calibration curves in the determination of pramipexole dihydrochloride monohydrate by HPLC 
and first derivative spectrophotometry
Method HPLC First derivative spectrophotometry
Wavelength, nm 263 249 280
Linearity range (µg/mL) 10–30 5−35 5−35
Slope 4.74 0.94 1.29
Intercept 5.6 x 10-4 2.0 x 10-4 1.2 x 10-3
Correlation coefficient, R2 0.9997 0.9911 0.9971
LOD (ng/mL) 8 2.0 1.5
LOQ (ng/mL) 50 6.1 4.5
TABLE VII - Results of the HPLC and first derivative spectrophotometry for the estimation of pramipexole dihydrochloride 
monohydrate in Pexola® Tablet 1.0 mg
HPLC 
263 nm (%)
First derivative spectrophotometry
249 nm (%) 280 nm (%)
Sample 1 99.4 107.4 101.9
Sample 2 99.3 107.4 101.9
Sample 3 99.3 107.4 101.9
Sample 4 97.6 107.4 101.9
Sample 5 100.2 107.4 101.9
Mean % 99.2 107.4 101.9
S.D. 0.97 0.00 0.00
R.S.D % 0.97 0.00 0.00
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TABLE VIII - The comparison of the parameters of the chromatographic and spectrophotometric methods developed for the 
determination of pramipexole dihydrochloride monohydrate
Method HPLC Method UV Spectrophotometry
Device Agilent HPLC 1200 Device Shimadzu UV-1601
Detector UV Detector UV
Column LiChrospher 60 RP Select B 
125 x 4.0 mm, 5 µm
- -
Wavelength 263 nm Wavelength 263 nm
Flow rate 1 mL/min 1.Derivative 249 nm, 280 nm
Injection volume 20 µL - -
Column Temperature 25 °C - -
Mobile phase 0.01 M Ammonium acetate 
(pH 4.4): acetonitrile (35:65 
v/v)
- -
Solvent ISTD Solution (100.0 µg/mL 
tamsulosin HCl in Water)
Solvent 0.1 M HCl
Calibration curves (10.0–30.0) µg/mL/solvent 
(five solutions)
Calibration Curves (5.0–35.0) µg/mL solvent 
(seven solutions)
Standard solution 20.0 µg/m /solvent Standard Solution 20.0 µg/mL/solvent
Sample solution 1 Tablet/50 mL of solvent Sample Solution 1 Tablet/50 mL of solvent
Analysis time 6 minute Analysis Time 1 minute
interference from drug excipients. The procedures, and 
their application to pharmaceutical forms of pramipexole 
dihydrochloride monohydrate, represent a good alternative 
in routine laboratorial analyses. Either procedure could be 
used for this determination, depending on the availability 
of the necessary instrumentation.
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